Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Birzeit Pharmaceutical CoXPAE:BPC +0.27%87 Return-on-Tangible-Asset is 5.52% as of Mar. 2026, which is 39% below its 10-year median of 9.07. GuruFocus rates XPAE:BPC with a GF Score™ of 87/100 and a GF Value™ of $4.59 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Birzeit Pharmaceutical Co ranks better than 76.27% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Birzeit Pharmaceutical Co's annualizedNet Income for the quarter that ended in Mar. 2026 was $7.91 Mil. Birzeit Pharmaceutical Co's average total tangible assets for the quarter that ended in Mar. 2026 was $143.17 Mil. Therefore, Birzeit Pharmaceutical Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 5.52%.
The historical rank and industry rank for Birzeit Pharmaceutical Co's Return-on-Tangible-Asset or its related term are showing as below:
XPAE:BPC'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 4.08 Med: 9.07 Max: 14.12
Current: 9.33
During the past 13 years, Birzeit Pharmaceutical Co's highest Return-on-Tangible-Asset was 14.12%. The lowest was 4.08%. And the median was 9.07%.
XPAE:BPC's Return-on-Tangible-Asset is ranked better than 76.27% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 3.15
vs XPAE:BPC: 9.33
Birzeit Pharmaceutical Co (XPAE:BPC) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Birzeit Pharmaceutical Co Return-on-Tangible-Asset Related Terms
Birzeit Pharmaceutical Co Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Birzeit Pharmaceutical Co's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Birzeit Pharmaceutical Co Return-on-Tangible-Asset Chart
XPAE:BPC vs ZTS, UTHR, VTRS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Birzeit Pharmaceutical Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Birzeit Pharmaceutical Co Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Birzeit Pharmaceutical Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Birzeit Pharmaceutical Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 5.52% mean?
Birzeit Pharmaceutical Co (XPAE:BPC) has a Return-on-Tangible-Asset of 5.52% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Birzeit Pharmaceutical Co and its competitors. This is 39% below median its historical median of 9.07. Over the past decade, Birzeit Pharmaceutical Co's Return-on-Tangible-Asset has ranged from 4.08 to 14.12. According to the industry distribution chart, Birzeit Pharmaceutical Co ranks #239 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 23.7%.
Is Birzeit Pharmaceutical Co's Return-on-Tangible-Asset too high?
Birzeit Pharmaceutical Co's current Return-on-Tangible-Asset of 5.52% is 39% below median its 10-year median of 9.07. Over the past 10 years, this metric has ranged from a low of 4.08 to a high of 14.12. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.15. Birzeit Pharmaceutical Co's value of 5.52% is 75.2% above this industry median. Based on the distribution chart, Birzeit Pharmaceutical Co ranks #239 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Birzeit Pharmaceutical Co has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Birzeit Pharmaceutical Co's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Birzeit Pharmaceutical Co ranks #239 out of 1007 companies for Return-on-Tangible-Asset. This places Birzeit Pharmaceutical Co in the top 24% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.15. Birzeit Pharmaceutical Co's value of 5.52% is 75.2% above this benchmark. Historically, Birzeit Pharmaceutical Co's own Return-on-Tangible-Asset has ranged from 4.08 to 14.12 over the past decade. While the company's 10-year median is 9.07 vs. the industry median of 3.15, Birzeit Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.15, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Birzeit Pharmaceutical Co's current Return-on-Tangible-Asset of 5.52% is 75.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Birzeit Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Birzeit Pharmaceutical Co's current Return-on-Tangible-Asset is 5.52%, which is 39% below median its own 10-year median of 9.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Birzeit Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Birzeit Pharmaceutical Co (XPAE:BPC) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.59, compared to a current price of $3.66 — trading 20.3% below its estimated fair value. The current Return-on-Tangible-Asset is 5.52%, which is 39% below median its 10-year median of 9.07 and 75.2% above the Drug Manufacturers industry median of 3.15. Birzeit Pharmaceutical Co's overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Birzeit Pharmaceutical Co (XPAE:BPC), the current Return-on-Tangible-Asset is 5.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Birzeit Pharmaceutical Co (XPAE:BPC) Overvalued in 2026?
Based on GuruFocus' analysis, Birzeit Pharmaceutical Co stock appears to be undervalued.
The current stock price of $3.66 is trading 20.3% below its estimated GF Value™ of $4.59.
GuruFocus considers Birzeit Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for XPAE:BPC:
Return-on-Tangible-Asset: 5.52% (39% below median its 10-year median of 9.07)
GF Value™: $4.59 vs. price of $3.66 (20.3% below fair value)
Industry Position: 75.2% above the Drug Manufacturers median (#239 of 1007)
No single metric tells the full story. See the XPAE:BPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Birzeit Pharmaceutical Co operates as a pharmaceutical manufacturer in Palestine, producing a range of approximately 270 products across various production lines at four locations. Its portfolio comprises brands spanning multiple therapeutic areas. In addition to manufacturing, the company supplies its products to the local market through pharmacies and medical professionals.
87GF Score
Get the complete analysis for XPAE:BPC
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAE:BPC has been successfully added to your 
